Patents by Inventor Xuejian Wang

Xuejian Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MULTIFUNCTIONAL IMMUNITY-TARGETED MICROMOLECULE ANTI-CANCER MEDICINE BESTAZOMIB (BESTAZOMIB) AND PREPARATION METHOD AND APPLICATION THEREOF
    Publication number: 20210300949
    Abstract: A multifunctional immunity-targeted micromolecule anti-cancer medicine Citrate Bestazomib and preparation method and application thereof. The structure of the multifunctional immunity-targeted micromolecule anti-cancer medicine Bestazomib Citrate is shown as follows: The multifunctional immunity-targeted micromolecule anti-cancer medicine Citrate Bestazomib has an activity-inhibiting effect on APN/CD13, also has an activity-inhibiting effect on tumor proteasome, and can be applied to the development of medicines for treating malignant tumors.
    Type: Application
    Filed: August 5, 2019
    Publication date: September 30, 2021
    Inventors: Wenfang XU, Jian ZHANG, Yuqi JIANG, Xiaobo XU, Xiaoyang LI, Leqiao TAN, Yongxue HUANG, Xuejian WANG, Zhen ZHANG
  • Multi-targeted Ubenimex prodrug derivative and preparation method and use thereof
    Patent number: 9861703
    Abstract: The present invention relates to the design, synthesis, and biological study of multi-targeted Ubenimex pro-drug derivative. More particularly, provided in the present invention is a compound as shown by general structural formula (I) (wherein the definition of R is shown in the description). The derivative is a multi-targeted compound obtained by binding an aminopeptidase (APN/CD13) inhibitor, Ubenimex, with some anti-tumor drugs already on the market through an ester bond or amide bond, and is suitable for use as an anti-tumor drug for the treating various malignant tumors, and is especially suitable for treating various solid tumors.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: January 9, 2018
    Assignee: Jinan Platinum Pharmatech Co. Ltd.
    Inventors: Wenfang Xu, Yuqi Jiang, Yingjie Zhang, Mingming Zou, Jinning Hou, Jin Li, Xuejian Wang, Xiaoyang Li
  • MULTI-TARGETED UBENIMEX PRODRUG DERIVATIVE AND PREPARATION METHOD AND USE THEREOF
    Publication number: 20160193347
    Abstract: The present invention relates to the design, synthesis, and biological study of multi-targeted Ubenimex pro-drug derivative. More particularly, provided in the present invention is a compound as shown by general structural formula (I) (wherein the definition of R is shown in the description). The derivative is a multi-targeted compound obtained by binding an aminopeptidase (APN/CD13) inhibitor, Ubenimex, with some anti-tumor drugs already on the market through an ester bond or amide bond, and is suitable for use as an anti-tumor drug for the treating various malignant tumors, and is especially suitable for treating various solid tumors.
    Type: Application
    Filed: June 6, 2014
    Publication date: July 7, 2016
    Applicant: WEIFANG BOCHUANG INTERNATIONAL ACADEMY OF BIOTECHNOLOGY AND MEDICINE
    Inventors: Wenfang Xu, Yuqi Jiang, Yingjie Zhang, Mingming Zou, Jinning Hou, Jin Li, Xuejian Wang, Xiaoyang Li